VivoSeq
Metabolic & Endocrine

Nephrogenic Diabetes Insipidus

9

Pipeline Programs↗

1

Active Trials↗

7

Companies Involved↗

Nephrogenic Diabetes Insipidus is an early-stage landscape with 9 programs across 7 companies. The most active players are EMD Serono, Pfizer's Upjohn has merged with Mylan to form Viatris Inc., Regeneron. 1 therapy is approved.

Intelligence

Pipeline Metrics

Competitive Density

35/100

Pipeline Velocity

0/100

Mech. Concentration

20/100

Completion Rate

83/100

Attrition Rate

14/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

EMD Serono logo

EMD Serono

1 program

Phase 1P

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

1 program

Phase 2Regeneron logo

Regeneron

1 program

Phase 2AbbVie logo

AbbVie

1 program

PreclinicalV

Viatris Specialty LLC

1 program

PreclinicalS

Salix

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Trial Status

7

clinical trials

Completed5 · 71%
Active, not recruiting1 · 14%
Terminated1 · 14%

Clinical Trials

Trial Activity

7 trials

AMIloride for the Treatment of Nephrogenic Diabetes Insipidus for Patients With Bipolar Disorder Treated With Lithium
Active, not recruiting·AAssistance Publique - Hôpitaux de Paris·Phase 4·NCT05044611·148 enrolled
Pharmacologic Treatment of Congenital Nephrogenic Diabetes Insipidus
Completed·UUniversity of Colorado, Denver·N/A·NCT00478335·4 enrolled
Probenecid (PB) to Treat Hereditary Nephrogenic Diabetes Insipidus (NDI), ADPKD Treated With Tolvaptan, and Severely Polyuric Patients With Previous Lithium Administration
Completed·MMayo Clinic·Phase 2·NCT05190744·36 enrolled
Atorvastatin for the Treatment of Lithium-Induced Nephrogenic Diabetes Insipidus
Completed·LLady Davis Institute·Phase 2·NCT02967653·60 enrolled
Nephrogenic Diabetes Insipidus During Prolonged Sevoflurane Sedation in the ICU: a Retrospective Analysis
Completed·UUniversitair Ziekenhuis Brussel·N/A·NCT04939753·1,000 enrolled
Study of Genotype and Phenotype Expression in Congenital Nephrogenic Diabetes Insipidus
Completed·NNational Center for Research Resources (NCRR)·N/A·NCT00004360
Metformin and Congenital Nephrogenic Diabetes Insipidus
Terminated·EEmory University·Phase 1·NCT02460354·2 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)